

Appl. No. 09/585,817  
Amdt. dated June 4, 2003  
Reply to Office Action of December 4, 2002

PATENT

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-10: (Withdrawn)

Claim 11. (Currently Amended) A method of preventing or treating a prion disorder characterized by amyloid deposition in a mammalian subject, comprising administering to the subject a dosage of an agent effective to produce an immune response comprising antibodies against an amyloid component derived from a prion precursor protein (PrP) including genetic variants of the PrP associated with hereditary amyloidosis characteristic of said disorder and an adjuvant that augments the immune response to the amyloid component, and thereby preventing or treating the disorder.

Claims 12-13: (Canceled)

Claim 14. (Original) The method of claim 13 11, wherein said agent induces an immune response directed against a neoepitope formed by said amyloid component with respect to said precursor protein.

Claim 15. (Currently Amended) The method of claim 13 11, wherein said amyloid component is selected from the group consisting of AA, AL, ATTR, AapeA1, Alys, Agel, Aey5, A $\beta$ , AB $_2$ M, ASer, AScr PrP D178N, Acal, AIAPP and synuclein NAC fragment.

Claim 16. (Currently Amended) The method of claim 15, wherein said agent is selected from the group consisting of AA, AL, ATTR, AapeA1, Agel, Aey5, A $\beta$ , AB $_2$ M, AScr, Acal, AIAPP and synuclein NAC fragment or PrP.

Claims 17-18: (Canceled)

Claim 19. (Original) The method of claim 11, wherein said agent is a peptide linked to a carrier moleculeprotein.

Appl. No. 09/585,817  
Amdt. dated June 4, 2003  
Reply to Office Action of December 4, 2002

PATENT

Claim 20. (Canceled)

Claim 21. (Currently Amended) The method of claim 2011, wherein said adjuvant is selected from the group consisting of QS21, monophosphoryl lipid, and alum and Freund's adjuvant.

Claim 22. (Currently Amended) The method of claim 11, wherein said immunological immune response is characterized by a serum titer of the antibodies of at least 1:1000 with respect to said amyloid component.

Claim 23. (Currently Amended) The method of claim 22, wherein said serum titer of the antibodies is at least 1:5000 with respect to said fibril amyloid component.

Claim 24. (Currently Amended) The method of claim 11, wherein said immunological immune response is characterized by a serum amount titer of immunoreactivity the antibodies against the amyloid component corresponding to greater than about four times higher than a serum level titer of immunoreactivity antibodies measured in a pre-treatment control serum sample.

Claim 25. (Currently Amended) The method of claim 24, wherein said serum amount titer of immunoreactivity the antibodies is measured at a serum dilution of about 1:100.

Claims 26-57: (Canceled)